WuXi’s New Unit Joins Race For Drug Innovation In China
This article was originally published in The Pink Sheet Daily
Executive Summary
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.
You may also be interested in...
Low Sinopharm Protection In Elderly Casts New Doubt On Chinese COVID-19 Vaccines
A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.
As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative
The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.
Fosun-BioNTech mRNA Vaccine Nears China Green Light
There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines.